POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast Cancer
January 6th 2023Jamie Carroll, APRN, CNP, MSN, weighs in on how findings from the POSITIVE study may change dialogue surrounding pregnancy for women with estrogen receptor–positive breast cancer who wish to pause adjuvant therapy.
Antidiarrheal Prophylaxis Remains a Key Focus in TKI Treatment for Patients with HER2+ Breast Cancer
January 4th 2023Loperamide prophylaxis was linked to low rates of grade 3 diarrhea in patients receiving adjuvant pyrotinib, but better antidiarrheal prophylaxis options are still needed in this setting.
Ovarian Suppression Treatment Is Rare for Premenopausal Women with HR+/HER2+ Breast Cancer
December 12th 2022In real-world practice, use of ovarian suppression therapy was not common among premenopausal patients with hormone receptor–positive, HER2-positive breast cancer, with tamoxifen being the preferred endocrine therapy.
Trastuzumab Deruxtecan Outperforms Trastuzumab Emtansine in DESTINY-Breast03 Follow-Up
December 8th 2022Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
Forgoing Select Lymph Node Dissection Linked With Superior Outcomes in Early-Stage Breast Cancer
December 28th 2021Updates from the ongoing INSEMA trial suggest that patients with early-stage breast cancer maintain superior quality of life by forgoing sentinel lymph node biopsy and axillary lymph node dissection.